On May 5, 2026, Embecta released its second quarter fiscal 2026 financial results, revealing that revenue had declined over 14%, largely due to weakness in its pen needle sales. Additionally, the ...

Embecta Corp. (NASDAQ: EMBC) faces a securities class action lawsuit, which seeks to represent investors who purchased or acquired Embecta common stock ...

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN EMBECTA CORP. (EMBC), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Embecta Corp. misrepresented demand for the needles it makes for insulin pens, leading to a recent 58% stock drop on disappointing financials, an investor alleges.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Embecta Corp. (NASDAQ:EMBC) posted on Friday the second-quarter 2025 adjusted earnings of 70 cents per share, up from 67 cents a year ago, beating the consensus of 53 cents. The diabetes care company ...

Analysts' tone was neutral to slightly positive, focusing on modeling guidance and pressing for details on China, margins, and capital allocation. Thibault and Mahoney congratulated management on the ...

Becton, Dickinson and Co.’s board of directors approved the company’s diabetes spinoff, and set a date of April 1 for the move. The announcement of Embecta Corp.’s approval came Feb. 1, along with a ...

View Embecta Corporation EMBC stock quote prices, financial information, real-time forecasts, and company news from CNN.

It’s official: Embecta Corp. is now one of the largest pure-play diabetes management companies worldwide. On April 1, Franklin Lakes-based BD announced it completed the spinoff of its former Diabetes ...